Skip to main content

Table 1 Basic anthropometric characteristics, biochemical data, and medical prescription in the T2DM patients

From: Gender-specific impacts of thigh skinfold thickness and grip strength for predicting osteoporosis in type 2 diabetes

 

Females

Males

p value

(n = 60)

(n = 43)

 

Age (years)

68.8 [63.2; 72.6]

67.5 [60.3; 71.4]

0.164

BMI (kg/m2)

25.0 [21.9; 27.2]

26.1 [23.1; 29.8]

0.082

Waist-to-hip ratio

0.94 [0.89; 1.01]

0.98 [0.92; 1.04]

0.032*

Systolic BP (mmHg)

134 [123; 146]

134 [123; 145]

0.807

Diastolic BP (mmHg)

74 [67; 81]

79 [72; 83]

0.095

Fasting glucose (mg/dL)

129 [105; 153]

131 [112; 147]

0.896

HbA1c %

HbA1c (mmol/mol)

7.5 [6.6; 8.2]

(58 [49; 66])

7.1 [6.6; 8.1]

(54 [49; 65])

0.388

LDL cholesterol (mg/dL)

91 [71; 105]

80 [69; 102]

0.360

Triglyceride (mg/dL)

108 [77; 136]

101 [76; 155]

0.960

Creatinine (mg/dL)

0.7 [0.6; 0.8]

1.0 [0.9; 1.2]

< 0.001**

ALT (U/L)

18 [15; 25]

20 [13; 26]

0.804

Years of diabetes

10 [6; 20]

10 [5; 19]

0.719

Smoking % (n)

0% (0)

30.2% (13)

< 0.001**

Alcohol drinking % (n)

1.7% (1)

32.6% (14)

< 0.001**

Statin % (n)

81.7% (49)

74.4% (32)

0.376

Metformin % (n)

73.3% (44)

83.7% (36)

0.212

AGI % (n)

8.3% (5)

14% (6)

0.362

SU or glinide % (n)

51.7% (31)

62.8% (27)

0.262

TZD % (n)

6.7% (4)

14% (6)

0.218

SGLT2i % (n)

26.7% (16)

44.2% (19)

0.064

DPP4i % (n)

33.3% (20)

27.9% (12)

0.557

GLP1RA % (n)

13.3% (8)

11.6% (5)

0.797

Insulin % (n)

35% (21)

27.9% (12)

0.447

  1. Continuous variables were analyzed using the Mann-Whitney U-test and are presented as median values and [quartiles]; Categorical variables were analyzed using the Chi-square test and are presented as percentages (number). Abbreviations: BMI, body mass index; BP, blood pressure; HbA1c, glycated hemoglobin; LDL, low density lipoprotein; ALT, alanine aminotransferase; AGI, alpha glucosidase inhibitor; SU, sulfonylurea; TZD, thiazolidinedione; SGLT2i, sodium-glucose co-transporter 2 inhibitor; DPP4i, dipeptidyl peptidase 4 inhibitor;
  2. GLP1RA, glucagon-like peptide 1 receptor agonist. *p < 0.05; **p < 0.001